ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
Zivo Bioscience has reported progress in licensing its coccidiosis treatment for broiler chickens. Following positive results from a 42-day study announced in August 2024, Zivo is discussing an exclusive license with major global animal health companies. Due diligence processes are underway, including technical evaluations, patent reviews, and business case assessments. Formal negotiations are expected to start in January 2025, with an agreement anticipated in Q1 2025. Zivo aims for a deal with upfront payment, milestone payments, and royalties. CEO John B. Payne highlighted the product's potential to enhance ionophores and vaccines. Additionally, Zivo is advancing its product targeting Low Pathogenicity Avian Influenza (LPAI) virus in poultry, planning further studies at the University of Delaware to optimize dosage and formulation. Payne noted the active ingredients' effectiveness against both parasitic and viral diseases, offering commercial opportunities.
Zivo Bioscience ha riportato progressi nella licenza del proprio trattamento per la coccidiosi nei polli da carne. A seguito di risultati positivi da uno studio di 42 giorni annunciato nell'agosto 2024, Zivo sta discutendo una licenza esclusiva con importanti aziende globali nel settore della salute animale. Sono in corso processi di due diligence, che includono valutazioni tecniche, revisioni di brevetti e valutazioni di business case. Le negoziazioni formali dovrebbero iniziare a gennaio 2025, con un accordo previsto per il primo trimestre del 2025. Zivo mira a un accordo con pagamento anticipato, pagamenti per traguardi e royalty. Il CEO John B. Payne ha evidenziato il potenziale del prodotto nel migliorare gli ionofori e i vaccini. Inoltre, Zivo sta sviluppando il proprio prodotto mirato al virus dell'Influenza Aviaria a Bassa Patogenicità (LPAI) negli uccelli da allevamento, pianificando ulteriori studi presso l'Università del Delaware per ottimizzare dosaggio e formulazione. Payne ha sottolineato l'efficacia degli ingredienti attivi contro malattie parassitarie e virali, offrendo opportunità commerciali.
Zivo Bioscience ha reportado avances en la licencia de su tratamiento para la coccidiosis en pollos de engorde. Luego de resultados positivos de un estudio de 42 días anunciado en agosto de 2024, Zivo está discutiendo una licencia exclusiva con importantes empresas globales de salud animal. Los procesos de debida diligencia están en marcha, incluyendo evaluaciones técnicas, revisiones de patentes y evaluaciones del caso de negocio. Se espera que las negociaciones formales comiencen en enero de 2025, con un acuerdo previsto para el primer trimestre de 2025. Zivo busca un acuerdo con pago inicial, pagos por hitos y regalías. El CEO John B. Payne destacó el potencial del producto para mejorar ionóforos y vacunas. Además, Zivo está avanzando con su producto dirigido al virus de la Influenza Aviar de Baja Patogenicidad (LPAI) en aves de corral, planificando más estudios en la Universidad de Delaware para optimizar la dosis y la formulación. Payne señaló la efectividad de los ingredientes activos contra enfermedades parasitarias y virales, ofreciendo oportunidades comerciales.
자이보 생명과학(Zivo Bioscience)이 육계용 코크시디오시스 치료제 라이센스 진행 상황을 보고했습니다. 2024년 8월 발표된 42일 연구의 긍정적인 결과를 바탕으로 자이보는 주요 글로벌 동물 건강 회사들과 독점 라이센스 협상 중입니다. 기술 평가, 특허 검토 및 사업 사례 평가와 같은 실사 과정이 진행 중입니다. 공식 협상은 2025년 1월에 시작될 것으로 예상되며, 2025년 1분기 동안 협약이 예상됩니다. 자이보는 선불금, 이정표 지급 및 로열티를 포함하는 계약을 목표로 하고 있습니다. CEO인 존 B. 페인(John B. Payne)은 제품이 이오노포르 및 백신을 향상시킬 수 있는 잠재력을 강조했습니다. 또한, 자이보는 가금류의 저병원성 조류인플루엔자(LPAI) 바이러스를 타겟으로 한 제품을 개발하고 있으며, 델라웨어 대학교에서 복용량 및 제형을 최적화하기 위한 추가 연구를 계획하고 있습니다. 페인은 활성 성분이 기생충 및 바이러스 질병에 대한 효과를 보이며 상업적 기회를 제공한다고 언급했습니다.
Zivo Bioscience a signalé des avancées dans la licence de son traitement contre la coccidiose pour les poulets de chair. Suite aux résultats positifs d'une étude de 42 jours annoncée en août 2024, Zivo est en discussion pour une licence exclusive avec de grandes entreprises mondiales de santé animale. Les processus de diligence raisonnable sont en cours, y compris les évaluations techniques, les révisions de brevets et les évaluations des cas commerciaux. Les négociations formelles devraient commencer en janvier 2025, avec un accord anticipé pour le premier trimestre 2025. Zivo vise à conclure un accord comprenant un paiement initial, des paiements d'étape et des redevances. Le PDG John B. Payne a souligné le potentiel du produit pour améliorer les ionophores et les vaccins. De plus, Zivo fait progresser son produit ciblant le virus de l'Influenza Aviaire de Basse Pathogénicité (LPAI) chez les volailles, prévoyant d'autres études à l'Université du Delaware pour optimiser le dosage et la formulation. Payne a noté l'efficacité des ingrédients actifs contre les maladies parasitaires et virales, offrant des opportunités commerciales.
Zivo Bioscience hat Fortschritte bei der Lizenzierung seiner Behandlung von Coccidiose bei Masthühnern gemeldet. Nach positiven Ergebnissen einer 42-tägigen Studie, die im August 2024 angekündigt wurde, diskutiert Zivo eine exklusive Lizenz mit großen globalen Unternehmen im Bereich der Tiergesundheit. Due-Diligence-Prozesse sind im Gange, einschließlich technischer Bewertungen, Patentreviews und Geschäftsanalyse. Die formellen Verhandlungen werden voraussichtlich im Januar 2025 beginnen, mit einer Einigung, die im ersten Quartal 2025 erwartet wird. Zivo strebt einen Vertrag mit Vorauszahlung, Meilensteinzahlungen und Lizenzgebühren an. CEO John B. Payne hob das Potenzial des Produkts hervor, Ionophore und Impfstoffe zu verbessern. Darüber hinaus entwickelt Zivo ein Produkt, das auf das Virus der Niedrigpathogenen Aviären Influenza (LPAI) bei Geflügel abzielt, und plant weitere Studien an der University of Delaware zur Optimierung von Dosierung und Formulierung. Payne betonte die Wirksamkeit der aktiven Inhaltsstoffe gegen parasitäre und virale Krankheiten und bietet gewerbliche Chancen.
- Zivo expects to enter formal negotiations for licensing its coccidiosis treatment in January 2025.
- Positive results from a 42-day coccidiosis study announced in August 2024.
- Potential licensing deal includes upfront payment, milestone payments, and royalties.
- The product can enhance the efficacy of ionophores and vaccines.
- Advancement in product targeting Low Pathogenicity Avian Influenza (LPAI) virus.
- No assurance of successfully negotiating a definitive agreement.
Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025
Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive license for ZIVO’s product. Prospective licensees are actively pursuing their respective due diligence processes, including technical evaluations, patent reviews and business case assessments.
Assuming the satisfactory completion of due diligence, ZIVO expects to enter into formal negotiations next month with the goal of finalizing an agreement in the first quarter of 2025. ZIVO intends to pursue deal terms that includes an upfront payment, milestone payments tied to commercialization targets and a royalty based on product sales.
“We are focused on securing an agreement that aligns with our commercialization strategy and delivers long-term value to our shareholders. Although our license dialogues remain ongoing and there can be no assurance we will be successful in negotiating a definitive agreement, we are highly encouraged by the progress we have made over the past four months and by the level of interest expressed by prospective partners. Our product holds potential as a standalone treatment and also can enhance the efficacy of ionophores and vaccines, representing a compelling and transformative value proposition for the poultry industry,” said John B. Payne, Chairman and Chief Executive Officer of ZIVO Biosciences.
In addition, building upon last week’s announcement of preliminary efficacy against avian influenza in poultry, the Company reports that it intends to advance development work on its product candidate targeting transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry flocks. ZIVO plans to initiate additional studies at the University of
“To date our active ingredients have demonstrated effectiveness against both parasitic and viral diseases. This remarkable versatility provides distinct commercial opportunities, including as a combination product in viral indications,” added Mr. Payne.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, with the estimated annual costs in excess of
About ZIVO Bioscience
Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241223509640/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
Source: Zivo Bioscience, Inc.
FAQ
What progress has Zivo Bioscience made with its coccidiosis treatment?
What are the expected terms of the Zivo coccidiosis treatment license?
When did Zivo announce positive results for its coccidiosis study?
What are the potential benefits of Zivo's coccidiosis product?
What additional developments is Zivo pursuing in poultry health?
What has Zivo's CEO said about the product's commercial potential?
What due diligence processes are prospective licensees undertaking?
